4-[2-pyridin-4-yl-5-[3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine
C25H20F3N7O — CID 163266601
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[2-pyridin-4-yl-5-[3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine
4-[2-pyridin-4-yl-5-[3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine (PubChem CID 163266601) has the molecular formula C25H20F3N7O and a molecular weight of 491.48 g/mol. Its IUPAC name is 4-[2-pyridin-4-yl-5-[3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine.
Molecular Properties
| Compound Name | 4-[2-pyridin-4-yl-5-[3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine |
|---|---|
| PubChem CID | 163266601 |
| Molecular Formula | C25H20F3N7O |
| Molecular Weight | 491.48 g/mol |
| Exact Mass | 491.17 |
| IUPAC Name | 4-[2-pyridin-4-yl-5-[3-[4-(trifluoromethyl)phenyl]pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine |
| SMILES | FC(F)(F)c1ccc(-c2ccn(-c3cc(N4CCOCC4)n4nc(-c5ccncc5)cc4n3)n2)cc1 |
| InChI | InChI=1S/C25H20F3N7O/c26-25(27,28)19-3-1-17(2-4-19)20-7-10-34(31-20)22-16-24(33-11-13-36-14-12-33)35-23(30-22)15-21(32-35)18-5-8-29-9-6-18/h1-10,15-16H,11-14H2 |
| InChIKey | UUIIRNSQUBDLED-UHFFFAOYSA-N |
| XLogP | 4.50 |
| TPSA | 73.37 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 491.48 |
| LogP ≤ 5 | 4.50 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163266601 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.